Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LITS

Lite Strategy Inc

Apr 13 • 12:48PM ET

1.12

-0.04 -3.45 %

Healthcare • Biotechnology • USA • NASD

Peers: IOVA ARQT FATE APLS ENTA KPTI GERN IMMP ONCT

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.74	Insider Own	11.27%	Shs Outstand	36.65M	Perf Week	-1.75%
Market Cap	40.73M	Forward P/E	-	EPS next Y	-	Insider Trans	-12.93%	Shs Float	32.27M	Perf Month	-2.61%
Enterprise Value	31.97M	PEG	-	EPS next Q	-	Inst Own	22.74%	Short Float	0.29%	Perf Quarter	-23.81%
Income	-39.70M	P/S	-	EPS this Y	-	Inst Trans	-7.05%	Short Ratio	0.26	Perf Half Y	-55.91%
Sales	0.00M	P/B	0.50	EPS next Y	-	ROA	-73.98%	Short Interest	0.09M	Perf YTD	-15.15%
Book/sh	2.23	P/C	4.65	EPS next 5Y	-	ROE	-76.38%	52W High	9.00 -87.56%	Perf Year	-40.11%
Cash/sh	0.24	P/FCF	-	EPS past 3/5Y	37.89% 25.03%	ROIC	-48.50%	52W Low	0.95 17.77%	Perf 3Y	-69.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.36% 5.40%	Perf 5Y	-97.97%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	69.71%	Oper. Margin	-	ATR (14)	0.07	Perf 10Y	-95.16%
Dividend Ex-Date	Nov 16, 2023	Quick Ratio	10.04	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	46.00	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	10.04	EPS Q/Q	-105.10%	SMA20	-3.16%	Beta	0.26	Target Price	22.67
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-1.18%	Rel Volume	0.60	Prev Close	1.16
Employees	4	LT Debt/Eq	0.00	Earnings	-	SMA200	-52.95%	Avg Volume	353.56K	Price	1.12
IPO	Dec 18, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	116,068	Change	-3.45%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Downgrade	Laidlaw	Buy → Hold
Mar-25-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$13 → $2
Mar-25-22	Downgrade	Stifel	Buy → Hold	$6 → $2
Mar-25-22	Downgrade	Jefferies	Buy → Hold	$4 → $1
Feb-03-22	Initiated	Jefferies	Buy	$4
Sep-22-20	Initiated	Alliance Global Partners	Buy	$9
May-29-20	Initiated	SunTrust	Buy	$16
Dec-20-18	Initiated	H.C. Wainwright	Buy	$10
Dec-20-18	Initiated	H.C. Wainwright	Buy
Jul-27-18	Upgrade	Stifel	Hold → Buy	$2.50 → $7
Jul-13-18	Initiated	SunTrust	Buy	$12
Apr-18-16	Reiterated	Wedbush	Neutral	$3 → $2
Mar-23-15	Downgrade	ROTH Capital	Buy → Neutral	$14 → $2.50
Dec-18-14	Reiterated	ROTH Capital	Buy	$22 → $14
Oct-16-14	Reiterated	ROTH Capital	Buy	$20 → $22
Jul-08-14	Resumed	Brean Capital	Buy	$16
Oct-22-13	Reiterated	Stifel	Buy	$11 → $15
Apr-15-13	Initiated	Stifel	Buy	$11

Show Previous Ratings

Feb-17-26 08:50AM	Lite Strategy Reports Fiscal 2026 Second Quarter Results (GlobeNewswire)
Nov-17-25 09:00AM	Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations (GlobeNewswire) -5.94%
Oct-29-25 09:00AM	Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations (GlobeNewswire) +7.77%
Oct-16-25 04:06PM	Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026 (GlobeNewswire) -13.15%
Sep-10-25 09:00AM	MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker LITS (Business Wire) +10.43%
04:23PM	Loading…
Aug-28-25 04:23PM	Crypto Treasury Boom Triggers Insider Trading Concerns Fortune Report (Cryptonews) -6.54%
07:00AM	Crypto hoarding brings a stock pop for small firmsand in some cases shows patterns of possible insider trading (Fortune)
Aug-25-25 09:47AM	Biotechs Turn to Digital Coins, Crypto to Boost Stock Prices (Bloomberg)
Aug-05-25 10:38AM	MEI Pharma Chooses Not Bitcoin, Not Ethereum, But Litecoin As Treasury Asset (Benzinga)
09:18AM	Litecoin Hits Five-Month High Amid ETF Optimism and $100M MEI Pharma Treasury (decrypt)
08:00AM	MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising (Business Wire)
Jul-22-25 04:35PM	MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange (Business Wire) -9.62%
Jul-20-25 12:35AM	MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange (Insider Monkey)
Jul-18-25 12:55PM	GSR Leads $100M Private Placement into Nasdaq-listed MEI Pharma to Launch First Institutional Litecoin Treasury Strategy Alongside Charlie Lee (etf.com) +31.56%
12:41PM	Crypto Market Value Tops $4 Trillion as Stablecoin Bill Passes (Bloomberg)
10:32AM	Loading…
10:32AM	BC-Most Active Stocks (Associated Press Finance)
09:42AM	Litecoin Surges 10%; Will $100M Bet by Nasdaq-Listed Company Fuel a Larger Rally? (CoinDesk)
08:30AM	MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange (Business Wire)
May-13-25 04:05PM	MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position (Business Wire) +6.22%
Mar-26-25 08:00AM	The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors (Business Wire)
Feb-12-25 04:12PM	MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position (Business Wire)
Nov-12-24 04:05PM	MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position (Business Wire)
Sep-19-24 04:01PM	MEI Pharma Reports Fiscal Year End 2024 Cash Position (Business Wire) -5.10%
Aug-12-24 08:30AM	MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives (Business Wire)
Jul-22-24 08:30AM	MEI Pharma to Consider Strategic Alternatives (Business Wire) +21.33%
Jul-01-24 02:18PM	7 Undervalued Biotech Stocks to Buy for Big-Time Returns (InvestorPlace)
May-09-24 10:57PM	MEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024 (InvestorPlace)
04:02PM	MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights (Business Wire)
Apr-11-24 08:02AM	MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 (Business Wire)
08:00AM	MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin) in Relapsed Metastatic Colorectal Cancer Patients (Business Wire)
08:00AM	Loading…
Apr-10-24 08:00AM	MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum (Business Wire)
Mar-26-24 08:00AM	MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia (Business Wire)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-13-24 06:15PM	MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -5.32%
05:05PM	MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights (Business Wire)
Feb-08-24 06:48AM	Is MEI Pharma (MEIP) Attractively Priced? (Insider Monkey)
Jan-16-24 05:00PM	MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024 (Business Wire) -11.55%
Dec-11-23 12:00PM	MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023 (Business Wire)
Nov-27-23 10:33AM	11 Cheapest Stocks With Biggest Upside (Insider Monkey) +6.61%
Nov-09-23 04:05PM	MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights (Business Wire)
Nov-08-23 08:00AM	MEI Pharma to Present at the Stifel 2023 Healthcare Conference (Business Wire)
Nov-06-23 04:57PM	MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock (Business Wire) +6.57%
Nov-02-23 11:23AM	Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View (Zacks)
09:00AM	MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023 (Business Wire)
Nov-01-23 12:03PM	Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
09:00AM	MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital (Business Wire)
Oct-20-23 11:43AM	BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank (Zacks)
Oct-18-23 11:13AM	Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up (Zacks)
Oct-17-23 05:33PM	MEI Pharma Recommends Stockholders Not to Consent (Business Wire)
11:47AM	Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD (Zacks)
11:30AM	AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review (Zacks)
Oct-16-23 12:53PM	Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse (Zacks)
Oct-10-23 10:54AM	Anson and Cable Car Send Letter to MEI Pharma Stockholders (GlobeNewswire)
Oct-02-23 06:00AM	MEI Pharma Adopts Limited-Duration Stockholder Rights Plan (Business Wire)
Sep-29-23 12:00PM	All You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong Buy (Zacks)
Sep-28-23 05:00PM	MEI Pharma Issues Statement Regarding Anson and Cable Cars Opportunistic Actions (Business Wire)
Sep-27-23 09:28AM	Q4 2023 MEI Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
09:12AM	MEI Pharma, Inc. (NASDAQ:MEIP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Sep-26-23 04:02PM	MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights (Business Wire)
05:03AM	Anson Funds Management LP Acquires Shares in MEI Pharma Inc (GuruFocus.com)
Sep-23-23 05:03AM	Anson Funds Management LP Acquires Additional Shares in MEI Pharma Inc (GuruFocus.com)
Sep-21-23 08:00AM	MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023 (Business Wire) +5.92%
Sep-18-23 08:00AM	MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car (Business Wire)
Sep-05-23 12:17PM	Three execs leave Infinity Pharmaceuticals after failed merger, layoffs (American City Business Journals)
Aug-16-23 08:00AM	MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer (Business Wire)
Jul-26-23 01:47PM	Cambridge biotech cuts most staffers after merger falls apart (American City Business Journals)
Jul-23-23 02:30PM	MEI Pharma Announces Results of Special Meeting of Stockholders (Business Wire)
Jul-19-23 08:00AM	MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction (Business Wire)
Jul-18-23 09:00AM	MEI Pharma Responds to Anson and Cable Car (Business Wire)
Jul-17-23 09:17AM	Anson and Cable Car File Preliminary Consent Materials to Remove Entire Board of Directors at MEI Pharma, Inc. (GlobeNewswire)
08:00AM	MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction (Business Wire)
Jul-13-23 04:05PM	MEI Pharma Postpones Special Meeting of Shareholders (Business Wire) +10.22%
Jul-11-23 08:00AM	MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals (Business Wire)
Jul-07-23 08:00AM	MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals (Business Wire)
Jul-05-23 08:00AM	MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote "FOR" Pending Transaction with Infinity Pharmaceuticals (Business Wire)
Jun-29-23 08:00AM	MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals (Business Wire)
Jun-27-23 05:15PM	MEI Pharma Responds to Anson and Cable Car (Business Wire)
09:20AM	Anson Funds and Cable Car Capital Issue Statement Regarding the Inferior Proposed Transaction between MEI Pharma and Infinity Pharmaceuticals (GlobeNewswire)
Jun-15-23 12:08PM	MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates (Business Wire)
Jun-13-23 08:00AM	MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor (Business Wire)
Jun-02-23 08:00AM	MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor (Business Wire)
Jun-01-23 04:22PM	Anson Funds and Cable Car Capital Issue Statement Regarding MEI Pharmas Rejection of Their Acquisition Proposal (GlobeNewswire)
08:00AM	MEI Pharma Board of Directors Rejects Unsolicited Proposal (Business Wire)
May-30-23 05:40PM	MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal (Business Wire) +6.94%
May-23-23 04:49PM	Clinical Triumph: MEI Pharma's Voruciclib Demonstrates Encouraging Activity in AML Patients (Benzinga)
08:00AM	MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies (Business Wire)
May-11-23 05:35PM	MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights (Business Wire)
May-09-23 08:35AM	Assertio (ASRT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-18-23 03:31PM	Lacklustre Performance Is Driving MEI Pharma, Inc.'s (NASDAQ:MEIP) Low P/S (Simply Wall St.)
Apr-14-23 04:15PM	MEI Pharma Announces 1-for-20 Reverse Stock Split (Business Wire)
Feb-23-23 12:14PM	Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge (Benzinga) -18.64%
07:00AM	MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates (Business Wire)
Feb-17-23 05:12AM	Rainbows and Unicorns: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Just Became A Lot More Optimistic (Simply Wall St.)
Feb-09-23 06:15PM	MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates (Zacks) -7.54% -10.34%
04:05PM	MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights (Business Wire)
Dec-06-22 04:00PM	MEI Pharma Announces Adjournment of Annual Meeting of Stockholders (Business Wire) -33.52% -7.65%
06:24AM	MEI Pharma, Kyowa Kirin Cull Development Of Blood Cancer Drug Outside Japan, Look For Strategic Alternatives (Benzinga)
Dec-05-22 05:01PM	MEI Pharma Initiates Strategic Realignment (Business Wire) -5.74%
05:00PM	MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting (Business Wire)

Lite Strategy, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. The company was founded on December 1, 2000, and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schornstein Alexander	10% Owner	Dec 18 '25	Sale	1.37	690,611	946,137	3,674,862	Dec 22 04:15 PM
Flynn James P	Director	Dec 19 '25	Buy	1.40	70,000	97,699	100,000	Dec 22 04:00 PM
Flynn James P	Director	Nov 19 '25	Buy	1.88	12,100	22,777	30,000	Nov 20 04:00 PM
Anson Funds Management LP	Former 10% Stockholder	Jul 28 '25	Proposed Sale	6.74	1,093,184	7,368,087		Jul 28 07:20 PM
Funicular Funds, LP	Former member of group that ow	Jul 23 '25	Proposed Sale	6.20	611,440	3,790,928		Jul 23 07:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LITS

Lite Strategy Inc

Upgrade your Finviz experience